These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16001382)

  • 1. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Schmidt-Erfurth U; Michels S; Michels R; Aue A
    Eur J Ophthalmol; 2005; 15(4):482-5. PubMed ID: 16001382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger DS; Luna SP; Robertson SM; Russell S; Singerman L; Slakter JS; Yannuzzi L; Zilliox P;
    Ophthalmology; 2003 Dec; 110(12):2372-83; discussin 2384-5. PubMed ID: 14644721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger S; Luna S; Robertson SM; Russell S; Singerman L; Slakter JS; Sullivan EK; Yannuzzi L; Zilliox P;
    Retina; 2003 Feb; 23(1):14-23. PubMed ID: 12652226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
    Aggermann T; Haas P; Binder S
    Ann Ophthalmol (Skokie); 2008; 40(1):28-30. PubMed ID: 18556978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anecortave acetate in the treatment of age-related macular degeneration.
    Augustin A
    Clin Interv Aging; 2006; 1(3):237-46. PubMed ID: 18046876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
    Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study.
    Eandi CM; Ober MD; Freund KB; Klais CM; Slakter JS; Sorenson JA; Yannuzzi LA
    Retina; 2006 Sep; 26(7):780-5. PubMed ID: 16963851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.